MediciNova, Inc. 10-Q Summary
Business Context and Reporting Period
MediciNova is a biopharmaceutical company developing small-molecule therapies for serious diseases with unmet medical needs, including MN-166 for neurological disorders, MN-221 for acute asthma exacerbations, MN-001 for NASH, and MN-029 for solid tumors. This unaudited Form 10-Q covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013.
Financial Performance and Position
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $0 | $3,257 |
| Operating expenses | $2.36 million | $2.42 million |
| Operating loss | $2.36 million | $2.42 million |
| Net loss attributable to common stockholders | $2.35 million | $2.42 million |
| Basic and diluted loss per share | $0.10 | $0.14 |
| Net cash provided by operating activities | $4.77 million | $(2.62) million |
| Cash and cash equivalents at period end | $14.78 million | $3.03 million |
Research, development and patent expense was $748,000, compared with $696,000 in the prior-year quarter. General and administrative expense decreased to $1.62 million from $1.72 million. Stock-based compensation was $255,000, compared with $158,000.
Cash provided by operating activities was primarily driven by collection in January 2014 of a $6.0 million receivable recorded in 2013. Financing activities provided $3.32 million, including $2.98 million from common-stock issuances, $304,000 from warrant exercises, and $30,000 from equity awards.
At March 31, 2014, total assets were $31.22 million, total liabilities were $4.57 million, and stockholders’ equity was $26.65 million. Working capital was $15.2 million. The filing does not report conventional debt or borrowings; liabilities primarily consisted of accounts payable, accrued expenses, a deferred tax liability, and deferred revenue.
Material Changes Versus the Prior Comparable Period
- Revenue declined to zero from $3,257 because no Kissei research and development service revenue was recognized in Q1 2014.
- Net loss improved by approximately $67,000, while loss per share improved to $0.10 from $0.14, partly reflecting a higher weighted-average share count.
- Operating cash flow improved by $7.39 million, principally because of collection of the $6.0 million Genzyme-related receivable and lower general and administrative spending.
- Cash increased by $8.08 million from December 31, 2013, to $14.78 million at March 31, 2014.
- The company sold 1.49 million common shares under its at-the-market facility during the quarter, generating approximately $3.0 million of net proceeds, and issued 17,476 shares under its employee stock purchase plan.
- Common shares outstanding increased to 24.09 million at March 31, 2014, from 22.50 million at December 31, 2013.
Guidance, Outlook, Risks, and Unusual Items
Management stated that it expected substantial net losses to continue for the next several years as development programs advance. Management believed available cash and working capital were sufficient to fund operations through June 30, 2015, but cautioned that resources might not support all planned research and development activities.
The company is pursuing additional financing through common-stock sales and strategic initiatives. The filing states that insufficient financing could require the company to sell programs or cease operations. The second at-the-market facility had a remaining aggregate offering capacity, although the filing does not state the unused amount at March 31, 2014. An additional $0.1 million of gross and net proceeds was generated from sales of 58,000 shares after quarter-end.
Key operating risks include clinical-development failure, regulatory uncertainty, dependence on future partnerships or licensing transactions, the need for additional capital, potential dilution from equity financing, and uncertainty regarding commercialization. The company had not entered into the required sublicense of MN-221 with its Zhejiang Sunmy joint venture and provided no assurance that the sublicense or Chinese development would proceed.
The company reported no material legal proceedings and no material changes to the risk factors disclosed in its 2013 Form 10-K. Goodwill of $9.6 million and in-process research and development of $4.8 million are subject to impairment testing. No impairment was reported for the quarter.
Important Facts for Investors to Verify
- Whether the company can generate partnership, milestone, or product revenue, given zero revenue in Q1 2014 and continued operating losses.
- The duration of the stated cash runway and the amount and terms of future financing required to execute planned clinical programs.
- The status, funding, and clinical milestones for MN-166, MN-221, MN-001, and MN-029.
- Whether the Zhejiang Sunmy joint venture obtains a sublicense for MN-221 and proceeds with development in China.
- The remaining capacity and potential dilution associated with the at-the-market equity facility, warrants, options, and convertible preferred stock.
- The collectability and timing of future revenue recognition from the remaining Kissei research and development services and other potential milestones.